SG11201913969SA - Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1 - Google Patents

Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1

Info

Publication number: SG11201913969SA
Authority: SG; Singapore
Prior art keywords: ccr4; hla; egfr; proteins binding; binding nkg2d
Prior art date: 2017-08-16

Application number

SG11201913969SA

Inventor

Gregory Chang

Ann Cheung

Jinyan Du

Asya Grinberg

William Haney

Dhruv Sethi

Nicolai Wagtmann

Bradley Lunde

Bianka Prinz

Original Assignee

Dragonfly Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-16

Filing date

2018-08-16

Publication date

2020-01-30

2018-08-16 Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc

2020-01-30 Publication of SG11201913969SA publication Critical patent/SG11201913969SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11201913969SA 2017-08-16 2018-08-16 Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1 SG11201913969SA (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201762546300P	2017-08-16	2017-08-16
US201762546297P	2017-08-16	2017-08-16
US201762552152P	2017-08-30	2017-08-30
US201762555114P	2017-09-07	2017-09-07
PCT/US2018/000212 WO2019035939A1 (en)	2017-08-16	2018-08-16	Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1

Publications (1)

Publication Number	Publication Date
SG11201913969SA true SG11201913969SA (en)	2020-01-30

Family

ID=65362495

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202102251YA SG10202102251YA (en)	2017-08-16	2018-08-16	Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
SG11201913969SA SG11201913969SA (en)	2017-08-16	2018-08-16	Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10202102251YA SG10202102251YA (en)	2017-08-16	2018-08-16	Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1

Country Status (12)

Country	Link
US (2)	US20200216544A1 (en)
EP (2)	EP3668893A4 (en)
JP (2)	JP2020531438A (en)
KR (2)	KR20200037388A (en)
CN (2)	CN113004391A (en)
AU (2)	AU2018318698A1 (en)
BR (1)	BR112020003050A2 (en)
CA (3)	CA3112990A1 (en)
IL (2)	IL272553A (en)
MX (2)	MX2020001805A (en)
SG (2)	SG10202102251YA (en)
WO (1)	WO2019035939A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI3579848T3 (en)	2017-02-08	2025-01-22	Dragonfly Therapeutics Inc	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP3582806B1 (en)	2017-02-20	2023-07-26	Dragonfly Therapeutics, Inc.	Proteins binding her2, nkg2d and cd16
EP4434587A3 (en)	2018-02-08	2025-01-01	Dragonfly Therapeutics, Inc.	Antibody variable domain combinations targeting the nkg2d receptor
SG11202007945UA (en)	2018-02-20	2020-09-29	Dragonfly Therapeutics Inc	Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
US20210363261A1 (en) *	2018-05-16	2021-11-25	Dragonfly Therapeutics, Inc.	Protein binding nkg2d, cd16 and a fibroblast activation protein
EA202091977A1 (en) *	2018-05-28	2021-02-09	Драгонфлай Терапьютикс, Инк.	MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
EA202091888A1 (en)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
US20230067182A1 (en) *	2019-11-29	2023-03-02	Boe Technology Group Co., Ltd.	Data Processing Device and Method, and Computer Readable Storage Medium
CN115708411A (en) *	2020-04-16	2023-02-21	南通壹宸生物医药科技有限公司	PD-1 mutant polypeptide and preparation and application thereof
US12157771B2 (en)	2020-05-06	2024-12-03	Dragonfly Therapeutics, Inc.	Proteins binding NKG2D, CD16 and CLEC12A
IL300249A (en) *	2020-08-05	2023-03-01	Dragonfly Therapeutics Inc	Proteins binding nkg2d, cd16 and egfr
CN116063550A (en) *	2020-09-02	2023-05-05	南京北恒生物科技有限公司	Chimeric antigen receptor targeting NK-activating receptor
CN115246886A (en) *	2021-04-27	2022-10-28	丹生医药技术(上海)有限公司	anti-EGFR/VEGF (epidermal growth factor receptor/vascular endothelial growth factor) bifunctional fusion protein and application thereof
WO2023284829A1 (en) *	2021-07-14	2023-01-19	江苏恒瑞医药股份有限公司	Antigen-binding molecule specifically binding to hgfr and eger, and pharmaceutical use thereof
CN116284430A (en) *	2021-07-30	2023-06-23	广东菲鹏制药股份有限公司	Tumor-targeted IL15 fusion protein and its application
EP4402178A2 (en) *	2021-09-16	2024-07-24	Biohaven Therapeutics Ltd.	Conjugated antibodies for treating diseases
EP4476263A2 (en) *	2022-02-09	2024-12-18	Dragonfly Therapeutics, Inc.	Pharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
WO2024027828A1 (en) *	2022-08-05	2024-02-08	Chimagen Biosciences, Ltd	Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen
WO2024213097A1 (en) *	2023-04-14	2024-10-17	山东先声生物制药有限公司	Multispecific antibody targeting human cd16 and tumor antigen
TW202502822A (en) *	2023-07-07	2025-01-16	大陸商四川科倫博泰生物醫藥股份有限公司	Egfr/c-met bispecific binding protein and use thereof
TW202502823A (en) *	2023-07-07	2025-01-16	大陸商四川科倫博泰生物醫藥股份有限公司	Egfr/c-met bispecific binding protein and use thereof
WO2025016453A1 (en) *	2023-07-19	2025-01-23	映恩生物制药（苏州）有限公司	Bispecific antibody, drug conjugate thereof, and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080299137A1 (en) *	2005-10-28	2008-12-04	Novo Nordisk A/S	Fusion Proteins That Bind Effector Lymphocytes And Target Cells
KR20100021601A (en) *	2007-05-14	2010-02-25	바이오겐 아이덱 엠에이 인코포레이티드	Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CA3102704A1 (en)	2007-12-14	2009-06-25	Novo Nordisk A/S	Antibodies against human nkg2d and uses thereof
WO2010017103A2 (en)	2008-08-04	2010-02-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic	Fully human anti-human nkg2d monoclonal antibodies
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2644698B1 (en) *	2010-11-17	2018-01-03	Chugai Seiyaku Kabushiki Kaisha	Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN107936121B (en) *	2011-05-16	2022-01-14	埃泰美德(香港)有限公司	Multispecific FAB fusion proteins and methods of use thereof
US8790651B2 (en) *	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
CN112079929A (en) *	2012-11-21	2020-12-15	武汉友芝友生物制药有限公司	bispecific antibody
IL284301B1 (en) *	2013-03-15	2025-06-01	Xencor Inc	Heterodimeric proteins
WO2015095412A1 (en)	2013-12-19	2015-06-25	Zhong Wang	Bispecific antibody with two single-domain antigen-binding fragments
NZ720353A (en) *	2013-12-30	2019-12-20	Epimab Biotherapeutics Inc	Fabs-in-tandem immunoglobulin and uses thereof
SG11201609917PA (en) *	2014-05-29	2016-12-29	Macrogenics Inc	Tri-specific binding molecules and methods of use thereof
US20170253658A1 (en) *	2014-08-28	2017-09-07	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
JP6734271B2 (en) *	2014-11-03	2020-08-05	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Methods for producing bispecific shark antibody variable domains and their use
AU2015373910B2 (en) *	2015-01-02	2021-11-18	Takeda Pharmaceutical Company Limited	Bispecific antibodies against plasma kallikrein and factor XII
WO2016122701A1 (en) *	2015-01-26	2016-08-04	Macrogenics, Inc.	Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
AU2016219785B2 (en)	2015-02-20	2021-10-28	Ohio State Innovation Foundation	Bivalent antibody directed against NKG2D and tumor associated antigens
WO2016191305A1 (en) *	2015-05-22	2016-12-01	The Board Of Trustees Of The Leland Stanford Junior University	Btn3a ectodomain proteins and methods of use
GB201517538D0 (en) *	2015-10-05	2015-11-18	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
BR112018013677A2 (en) *	2016-01-11	2019-01-22	Inhibrx Inc	multivalent and multispecific 41bb binding fusion proteins
EP3411407B1 (en) *	2016-02-05	2024-04-03	Orionis Biosciences BV	Bispecific signaling agents and uses thereof
AU2017222700B2 (en) *	2016-02-26	2018-09-27	Imunexus Therapeutics Limited	Multi-specific molecules

2018
- 2018-08-16 JP JP2020508477A patent/JP2020531438A/en active Pending
- 2018-08-16 US US16/638,559 patent/US20200216544A1/en not_active Abandoned
- 2018-08-16 EP EP18846836.7A patent/EP3668893A4/en not_active Withdrawn
- 2018-08-16 CN CN202110256674.8A patent/CN113004391A/en active Pending
- 2018-08-16 WO PCT/US2018/000212 patent/WO2019035939A1/en active Application Filing
- 2018-08-16 BR BR112020003050-3A patent/BR112020003050A2/en not_active IP Right Cessation
- 2018-08-16 EP EP21164058.6A patent/EP3882270A3/en active Pending
- 2018-08-16 SG SG10202102251YA patent/SG10202102251YA/en unknown
- 2018-08-16 MX MX2020001805A patent/MX2020001805A/en unknown
- 2018-08-16 CA CA3112990A patent/CA3112990A1/en active Pending
- 2018-08-16 SG SG11201913969SA patent/SG11201913969SA/en unknown
- 2018-08-16 KR KR1020207007137A patent/KR20200037388A/en not_active Ceased
- 2018-08-16 CA CA3073117A patent/CA3073117A1/en not_active Abandoned
- 2018-08-16 AU AU2018318698A patent/AU2018318698A1/en not_active Abandoned
- 2018-08-16 CN CN201880053214.1A patent/CN111065649A/en active Pending
- 2018-08-16 CA CA3176049A patent/CA3176049A1/en active Pending
- 2018-08-16 KR KR1020217006762A patent/KR20210029298A/en active Pending
2020
- 2020-02-09 IL IL272553A patent/IL272553A/en unknown
- 2020-02-14 MX MX2021002969A patent/MX2021002969A/en unknown
2021
- 2021-03-01 US US17/188,978 patent/US20210261668A1/en not_active Abandoned
- 2021-03-05 AU AU2021201451A patent/AU2021201451A1/en not_active Abandoned
- 2021-03-07 IL IL281305A patent/IL281305A/en unknown
- 2021-03-09 JP JP2021037440A patent/JP2021098732A/en active Pending

Also Published As

Publication number	Publication date
WO2019035939A1 (en)	2019-02-21
US20200216544A1 (en)	2020-07-09
EP3668893A4 (en)	2021-08-04
CN113004391A (en)	2021-06-22
EP3882270A2 (en)	2021-09-22
MX2020001805A (en)	2020-07-13
AU2018318698A1 (en)	2020-02-20
KR20200037388A (en)	2020-04-08
EP3882270A3 (en)	2021-12-01
MX2021002969A (en)	2021-05-12
KR20210029298A (en)	2021-03-15
IL281305A (en)	2021-04-29
IL272553A (en)	2020-03-31
CA3112990A1 (en)	2019-02-21
JP2021098732A (en)	2021-07-01
AU2021201451A1 (en)	2021-03-25
US20210261668A1 (en)	2021-08-26
CA3176049A1 (en)	2019-02-21
EP3668893A1 (en)	2020-06-24
CA3073117A1 (en)	2019-02-21
BR112020003050A2 (en)	2020-09-01
SG10202102251YA (en)	2021-04-29
CN111065649A (en)	2020-04-24
JP2020531438A (en)	2020-11-05

Publication	Publication Date	Title
IL272553A (en)	2020-03-31	Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
IL268567A (en)	2019-09-26	Proteins binding bcma, nkg2d and cd16
IL277398A (en)	2020-11-30	Pd-l1 binding affimers, and uses related thereto
IL268790A (en)	2019-10-31	Proteins binding cd33, nkg2d and cd16
IL268755A (en)	2019-10-31	Proteins binding her2, nkg2d and cd16
IL270794A (en)	2020-01-30	A protein binding nkg2d, cd16 and ror1 or ror2
EP3652212A4 (en)	2021-04-14	Antibodies binding lag-3 and uses thereof
EP3681532A4 (en)	2021-09-01	Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
SG11202000632QA (en)	2020-02-27	Proteins binding nkg2d, cd16 and flt3
IL268768A (en)	2019-10-31	Proteins binding gd2, nkg2d and cd16
IL268574A (en)	2019-09-26	Proteins binding psma, nkg2d and cd16
IL268766A (en)	2019-10-31	Proteins binding cd123, nkg2d and cd16
IL277519A (en)	2020-11-30	Antagonistic pd-1, pd-l1 and lag-3 binding proteins
IL280512A (en)	2021-03-25	Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
SG11202111012QA (en)	2021-11-29	Trispecific binding proteins, methods, and uses thereof
IL273202A (en)	2020-04-30	Binding proteins to the human thrombin receptor, par4
HK40014030A (en)	2020-08-14	Proteins binding bcma, nkg2d and cd16
HK40030226A (en)	2021-02-26	Proteins binding nkg2d, cd16 and flt3
AU2025204591A1 (en)	2025-07-10	Proteins binding NKG2D, CD16, FLT3
HK40014039A (en)	2020-08-14	Proteins binding cd33, nkg2d and cd16
ZA201905273B (en)	2023-06-28	Proteins binding psma, nkg2d and cd16
HK40019734A (en)	2020-10-16	Proteins binding cd123, nkg2d and cd16
HK40044284A (en)	2021-09-30	Pd-l1 binding affimers, and uses related thereto
HK40019178A (en)	2020-10-09	Proteins binding psma, nkg2d and cd16
HK40027628A (en)	2021-01-22	A protein binding nkg2d, cd16 and ror1 or ror2